Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion A/S, a clinical-stage TechBio company, has won the 2026 International Prix Galien Award for its AI-Immunology platform as the best digital health solution, marking the first time a Danish company has received this prestigious award. The recognition follows positive three-year phase 2 trial data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, which demonstrated 89% vaccine target precision and sustained T-cell responses.